Preview

Антибиотики и Химиотерапия

Расширенный поиск

Вопросы реабилитации и профилактики нежелательных явлений у больных, страдающих раком молочной железы и получающих антиэстрогенную терапию

Полный текст:

Аннотация

Описаны принципы проведения специфических реабилитационных мероприятий у пациенток, страдающих гормоночувствительным раком молочной железы, в зависимости от вида антиэстрогенной гормонотерпиии. С учётом различного механизма действия блокаторов антиэстрогенного воздействия - блокирования рецепторов эстрогенов, ингибирование ароматазы препаратами стероидного и нестероидного класса - разработаны программы реабилитации в зависимости от различного спектра побочных явлений антиэстрогенной терапии.

Об авторах

С. В. Стражев
Онкологический диспансер № 3 , Москва
Россия


П. В. Копосов
Городская поликлиника № 205, Москва
Россия


А. В. Белоногов
Городская поликлиника № 58, Москва
Россия


Список литературы

1. Возный Э.К. Рак молочной железы. Фармацев. вестн. 1998; 19: 10-11.

2. Горбунова В.А. Рак молочной железы: проблемы гормонотерапии. Новый мед. журн. 1998; 2: 7-11.

3. Моисеенко В.М., Семиглазов В.Ф.,Тюляндин С.А. Современное лекарственное лечение местнораспространённого и метастатического рака молочной железы. СПб.: 1997.

4. Горбунова В.А. Новые гормональные препараты для лечения рака. Материалы конференции «Современные тенденции развития лекарственной терапии опухолей», организованная ОНЦ РАМН при содействии ESMO, 9-10 декабря 1997, М. 30-35.

5. Семиглазов В.Ф. Стандарты лечения рака молочной железы (Сан-Галленб 2007). Совр. онкол. 2007; экстравыпуск: 3-7.

6. Семиглазов В.Ф., Канаев С.В., Бугрова И.Л. и др. Оценка эффективности адъювантной системной терапии при выполнении органосохраняющего лечения рака молочной железы. Вопр. онкол. 1998; 4: 408-413.

7. Arteaga С., Коіі К., Dugger Т. е1 а1. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst 1999; 91: 46-53.

8. Bermstein L., Deapen D., Cerhan J. et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. Breast Diseases 200; 11: 213.

9. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-942.

10. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.

11. Plourde P.V., Dyroff M., Dosett M. et аl. Arimidex: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Molec Biol 1995; 53: 175-179.

12. Scottish Cancer Trials Office (MRC): Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 1987; 330: 171-175.

13. Winer E.P. et al. American Society of Clinical Oncology. Technology assessment of the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer. Status Report 2002. J Clin Oncol 2002; 20: 3317-3327.

14. Yates R.A., Dowsett M., Fisher G.V. et аl. Arimidex ( ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996; 73: 543-548.

15. Baum M. Use of aromatase inhibitors in the adjuvant treatment of breast cancer. Endocrine-Related Cancer 1999; 6: 231-234.

16. Carlini P. et al. Exemestane is an effective 3rd line hormonal therapy for postmenopausal metastatic breast cancer patients pretreated with 3rd generation nonsteroidal aromatase inhibitors. Ann Oncol 2002; 13: Suppl 5: 48, abstr. 171P.

17. Coombes R.C. et al. A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal woman with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.

18. Goss P.E., Ingle J.N., Martino S. et al. Randomized trial of Letrozole following Tamoxifen as extended adjuvant therapy in receptor-positive breast cancer. J Natl Cancer Inst 2005; 97: 1267-1271.

19. Hayward J.L., Carbone P.P., Heuson J.-C. et al. Assessment of response to therapy in advanced breast cancer. Cancer 1977; 39: 1289-1294.

20. Howell A., Defriend D., Robertson J. et al. Response to specific antioestrogen (ICI182, 780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 29-30.

21. Dowsett M., Pfister C., Johnston S. et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Breast Diseases 2000; 11: 212.

22. Lonning P. et al. Activity of Exemestane (Aromasin) in breast cancer after failure of nonsteroidal aromatase inhibitors: phase II trial. J Clin Oncol 2000; 18: 2234-2244.

23. The ATAC trialists' group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.

24. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-γear survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.

25. Lykkesfeldt A. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol 1996; 35: 9-14.

26. Banks L., Girgis S., Coleman R. et al. Skeletal effect of exemestane in patients with breast cancer. J Bone Miner Res. 2005; 20 Suppl 1: S. 327.

27. Jones S. et al. Multicenter, phase II trial of Exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol 1999; 17: 3418-3425.

28. Walton P.L., Yates R.A., Dukes M. Arimidex: an overview of a new selective nonsteroidal aromatase inhibitor. In: Motta M., Serio M., eds. Sex Hormones and Antihormonts in Endocrine Dependent Pathology: Basic Clinical Aspects. Proceedings of an International Symposium, Milano, 10-14 April 1994. Amsterdam, New York: Elsevier, 1994; 311-316.

29. Stewart H.J., for the Scottish Breast Group. Adjuvant tamoxifen duration in a randomized trial. Breast 1995; 4: 256.

30. Fisher B., Jeong J.H., Bryant J. et al. Treatment of lymph-node-negative oestrogen-receptor-positive breast cancer: long-term findings from national surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004; 364: 858-868.

31. Fisher B., Digman J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer. Updated findings form the National Surgical Adjuvant Breast and Bowel Project B-14: randomized trial. J Natl Cancer Inst 2001; 93: 684-690.

32. Ingle J., Suman V., Johnson P. et al. Evaluation of tamoxifen plus letrozole with assesment of pharmacokinetic interaction in postmenopausal women. Breast Diseases 2000; 11: 210-211.

33. Bria E., Ciccarese M., Giannarelli D. et al. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. Cancer Treat Rew 2006; 32: 325-32.

34. Budzar A., Jonat W., Howell A. et al. Anastrozole vs megesterol acetate in treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature phase 111 trials. / Cancer 1998; 83 (8) 15th Sep: 1142-52.

35. Coombes R.C. et al. First mature survival analysis of the Intergroup Exemestane Study: a randomized trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2 to 3 years of adjuvant tamoxifen. Presented at: American Society of Clinical Oncologists (ASCO) Annual Meeting 2006.

36. Cuzick J., Howell A. Optimal timing of use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. J Clin Oncol 2005; 23: 658.

37. Jonat W., Zoladex T.M. (Goserelin) vs. CMF as adjuvant therapy in pre perimenopausal node-positive breast cancer: first efficacy results from ZEBRA Study. The Europ J of Cancer 2000; 36: Suppl 5: 67.

38. Kaufmann M. et al. Exemestane is superior to megestrol acetate following tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-1411.

39. Punglia R.S., Kuntz K.M., Winer E.P. et al. Optimizing adjuvant endocrine therapy in postmenopausal women with earlystage breast cancer: a decision analysis. J Clin Oncol 2005; 22: 5178-5187.

40. Robertson J.F.R., Lee D. Static disease (SD) of long duration (>24 weeks) is an impotant remission criteria in breast cancer patient treated with aromatase inhibitor «Arimidex» (anastrozole). Breast Cancer Res and Treat 1997; 46: 1 54: abstr. 214.

41. Brufsky A. et al. Zoledronic acid effectively inhibits cancer treatment-induced bone loss in postmenopausal women with carly breast cancer recciving adjuvant letrozole: 12-month BMD results of the Z-fast trial. Data presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO). Orlando, FL, USA. Abstract 533.

42. The Breast International Group (BIG) 1-98 Collaborative group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.

43. Wasan K.M. et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen. (NCIC CTG MA. 17L). Ann Oncol 2005; 16: 707-715.

44. ATAC trialists' Group. Эффективность адъювантной терапии анастрозолом и тамоксифеном у пациенток с ранними стадиями рака молочной железы: анализ данных исследования АТАС при медиане времени наблюдения 100 мес. (перевод с англ.). Lancet Oncol., 2008; 9: 45-53.

45. Geiser J., Bernsten H., Ottestad L. et al. Neoadjuvant treatment with anastrazol ('Arimidex') causes profound suppression of intra-tumor estrogen levels. Proceedings of the American Society of Clinical Oncology, 1999, 18 pp 82a Abs 311. 35th annual meeting of the American Society of Clinical Oncology, Athlanta, 15-18 May 1999.

46. Subar M. et al. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover and lipid metabolism in healthy volunteers. Proc ASCO 2004, abst. 8038.

47. Gelmon K.A., Pritchard K.I. Evaluating the impact of new data from aromatase inhibitor trials on clinical practice in early breast cancer: a Canadian thought leader perspective from drs. Karen Gelmon and Kathleen Pritchard. Medscape Hematology-Oncology 2006; 8: 2.

48. Paridaens R. et al. Mature results of a randomized phase II multicenter study of Exemestan versus Tamoxifen as first-line hormonal therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14: 1391-1398.

49. Paridaens R. et al. First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients - A randomized phase III trial of the EORTC Breast Group. Proc ASCO 2004, abst. 515.

50. Francini G., Petrioli R., Montagnani A. et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 2006; 95: 153-158.


Для цитирования:


Стражев С.В., Копосов П.В., Белоногов А.В. Вопросы реабилитации и профилактики нежелательных явлений у больных, страдающих раком молочной железы и получающих антиэстрогенную терапию. Антибиотики и Химиотерапия. 2012;57(1-2):32-40.

For citation:


Strazhev S.V., Koposov P.V., Belonogov A.V. Problems of Rehabilitation and Prophylaxis of Adverse Reactions to Antiestrogen Therapy in Patients with Breast Cancer. Antibiotics and Chemotherapy. 2012;57(1-2):32-40. (In Russ.)

Просмотров: 28


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0235-2990 (Print)